PDCD1 and non-small cell lung carcinoma: To the best of our knowledge, this systematic review is the first to compare the efficacy of PD-1 antibodies, pembrolizumab and nivolumab, as neoadjuvant therapies in NSCLC, with studies incorporating both regimens [17,31,32].